Matthew J. Bizzarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthew J. Bizzarro has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Ian Gross
Yale University School of Medicine; Department of Pediatrics; 333 Cedar Street WP493 P.O. Box 208064 New Haven CT USA 06520-8064
4 shared publicationsPatrick G. Gallagher
Division of Perinatal Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
3 shared publicationsRichard A. Ehrenkranz
Department of Pediatrics, Yale University School of Medicine, New Haven, CT
2 shared publicationsVeronika Northrup
Yale Center for Analytical Sciences, New Haven, CT
2 shared publicationsAlecia M. Thompson
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06520-8064, USA
1 shared publicationAmber M. Natusch
Neonatal Intensive Care Unit,Yale-New Haven Children's Hospital,New Haven,Connecticut
1 shared publication
Latest Publications
- 12 January 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 40 (4) , 365-367
Gastrointestinal Zygomycosis in a Preterm Neonate Associated With Contaminated Probiotics
A neonate of 29 weeks’ gestation who received probiotics developed clinical signs suggesting surgical necrotizing enterocolitis. A specimen of resected ileum revealed fungal forms within the bowel wall. Rhizopus oryzae was detected via DNA sequencing from probiotic powder and tissue specimens from the infant. To our knowledge, this is the first report linking gastrointestinal zygomycosis to the administration of contaminated probiotics.
- 12 January 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 40 (4) , 365-367
Gastrointestinal Zygomycosis in a Preterm Neonate Associated With Contaminated Probiotics
A neonate of 29 weeks’ gestation who received probiotics developed clinical signs suggesting surgical necrotizing enterocolitis. A specimen of resected ileum revealed fungal forms within the bowel wall. Rhizopus oryzae was detected via DNA sequencing from probiotic powder and tissue specimens from the infant. To our knowledge, this is the first report linking gastrointestinal zygomycosis to the administration of contaminated probiotics.
- 29 January 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 40 (3) , 357-358
Why so little progress in regionalization of perinatal care when transport of high-risk neonates remains a substantial risk?
- 29 January 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 40 (3) , 357-358
Why so little progress in regionalization of perinatal care when transport of high-risk neonates remains a substantial risk?
- Open Access
- 18 May 2018
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 1 (1) , e180165
Avoiding Unnecessary Antibiotic Exposure in Premature Infants
Early antibiotic treatment is common among premature infants given their significant risk of early-onset sepsis (EOS) and its related consequences, but prolonge
- 18 May 2018
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 1 (1) , e180165
Open AccessAvoiding Unnecessary Antibiotic Exposure in Premature Infants
Early antibiotic treatment is common among premature infants given their significant risk of early-onset sepsis (EOS) and its related consequences, but prolonge
- 1 June 2017
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 38 (10) , 1137-1143
Implementation of an Antimicrobial Stewardship Program in a Neonatal Intensive Care Unit
OBJECTIVE: To evaluate antimicrobial utilization and prescription practices in a neonatal intensive care unit (NICU) after implementation of an antimicrobial stewardship program (ASP).DESIGN: Quasi-experimental, interrupted time-series study.SETTING: A 54-bed, level IV NICU in a regional academic and tertiary referral center.PATIENTS AND PARTICIPANTS: All neonates prescribed antimicrobials from January 1, 2011, to June 30, 2016, were eligible for inclusion.INTERVENTION: Implementation of a NICU-specific ASP beginning July 2012.METHODS: We convened a multidisciplinary team and developed guidelines for common infections, with a focus on prescriber audit and feedback. We conducted an interrupted time-series analysis to evaluate the effects of our ASP. Our primary outcome measure was days of antibiotic therapy (DOT) per 1,000 patient days for all and for select antimicrobials. Secondary outcomes included provider-specific antimicrobial prescription events for suspected late-onset sepsis (blood or cerebrospinal fluid infection at >72 hours of life) and guideline compliance.RESULTS: Antibiotic utilization decreased by 14.7 DOT per 1,000 patient days during the stewardship period, although this decrease was not statistically significant (P=.669). Use of ampicillin, the most commonly antimicrobial prescribed in our NICU, decreased significantly, declining by 22.5 DOT per 1,000 patient days (P=.037). Late-onset sepsis evaluation and prescription events per 100 NICU days of clinical service decreased significantly (P<.0001), with an average reduction of 2.65 evaluations per year per provider. Clinical guidelines were adhered to 98.75% of the time.CONCLUSIONS: Implementation of a NICU-specific antimicrobial stewardship program is feasible and can improve antibiotic prescribing practices.Infect Control Hosp Epidemiol2017;38:1137–1143
- 1 June 2017
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 38 (10) , 1137-1143
Implementation of an Antimicrobial Stewardship Program in a Neonatal Intensive Care Unit
OBJECTIVE: To evaluate antimicrobial utilization and prescription practices in a neonatal intensive care unit (NICU) after implementation of an antimicrobial stewardship program (ASP).DESIGN: Quasi-experimental, interrupted time-series study.SETTING: A 54-bed, level IV NICU in a regional academic and tertiary referral center.PATIENTS AND PARTICIPANTS: All neonates prescribed antimicrobials from January 1, 2011, to June 30, 2016, were eligible for inclusion.INTERVENTION: Implementation of a NICU-specific ASP beginning July 2012.METHODS: We convened a multidisciplinary team and developed guidelines for common infections, with a focus on prescriber audit and feedback. We conducted an interrupted time-series analysis to evaluate the effects of our ASP. Our primary outcome measure was days of antibiotic therapy (DOT) per 1,000 patient days for all and for select antimicrobials. Secondary outcomes included provider-specific antimicrobial prescription events for suspected late-onset sepsis (blood or cerebrospinal fluid infection at >72 hours of life) and guideline compliance.RESULTS: Antibiotic utilization decreased by 14.7 DOT per 1,000 patient days during the stewardship period, although this decrease was not statistically significant (P=.669). Use of ampicillin, the most commonly antimicrobial prescribed in our NICU, decreased significantly, declining by 22.5 DOT per 1,000 patient days (P=.037). Late-onset sepsis evaluation and prescription events per 100 NICU days of clinical service decreased significantly (P<.0001), with an average reduction of 2.65 evaluations per year per provider. Clinical guidelines were adhered to 98.75% of the time.CONCLUSIONS: Implementation of a NICU-specific antimicrobial stewardship program is feasible and can improve antibiotic prescribing practices.Infect Control Hosp Epidemiol2017;38:1137–1143
- 21 November 2015
- Published by Springer Nature in Dysphagia
- Vol. 31 (2) , 154-159
Oral Alimentation in Neonatal and Adult Populations Requiring High-Flow Oxygen via Nasal Cannula
Use of high-flow oxygen via nasal cannula (HFO2-NC) is increasingly common in intensive care unit (ICU) settings. Despite the critical interface between respiration and swallowing, and the high acuity of patients in ICUs, the impact of HFO2-NC on feeding and swallowing is unknown. The present prospective, single-center, cohort study investigated the impact of HFO2-NC use on oral alimentation in neonatal and adult ICU patients. Oral alimentation status was evaluated in 100 consecutive ICU inpatients (50 neonatal and 50 adult) requiring HFO2-NC. Participant characteristics, respiratory support, successful initiation of oral feeding in neonates, and successful resumption of oral feeding in adults were recorded. Seventeen of 50 (34 %) neonates requiring HFO2-NC were deemed developmentally and medically appropriate by the neonatologist and nursing to begin oral alimentation. All 17 (100 %) were successful with initiation of oral feedings. Thirty-three of 50 (66 %) continued nil per os due to prematurity or medical conditions precluding oral alimentation at time of data collection. Thirty-nine of 50 (78 %) adults requiring HFO2-NC were deemed medically appropriate by the intensivist and nursing to resume oral alimentation (n = 34) or with a functional swallow without aspiration on FEES (n = 5). All 39 (100 %) resumed oral alimentation successfully. Eleven of 50 (22 %) continued nil per os due to severe respiratory issues precluding both swallow testing and oral alimentation at time of data collection. All developmentally and medically appropriate neonatal and adult patients requiring HFO2-NC were successful with either the introduction or resumption of oral alimentation. Patients requiring HFO2-NC who are identified as having feeding or swallowing issues should be referred for swallowing evaluations using the same criteria as patients who do not require HFO2-NC, as it is not the use of HFO2-NC but rather patient-specific determinants of feeding and swallowing readiness and their underlying medical conditions that impact readiness for oral alimentation status.
- 21 November 2015
- Published by Springer Nature in Dysphagia
- Vol. 31 (2) , 154-159
Oral Alimentation in Neonatal and Adult Populations Requiring High-Flow Oxygen via Nasal Cannula
Use of high-flow oxygen via nasal cannula (HFO2-NC) is increasingly common in intensive care unit (ICU) settings. Despite the critical interface between respiration and swallowing, and the high acuity of patients in ICUs, the impact of HFO2-NC on feeding and swallowing is unknown. The present prospective, single-center, cohort study investigated the impact of HFO2-NC use on oral alimentation in neonatal and adult ICU patients. Oral alimentation status was evaluated in 100 consecutive ICU inpatients (50 neonatal and 50 adult) requiring HFO2-NC. Participant characteristics, respiratory support, successful initiation of oral feeding in neonates, and successful resumption of oral feeding in adults were recorded. Seventeen of 50 (34 %) neonates requiring HFO2-NC were deemed developmentally and medically appropriate by the neonatologist and nursing to begin oral alimentation. All 17 (100 %) were successful with initiation of oral feedings. Thirty-three of 50 (66 %) continued nil per os due to prematurity or medical conditions precluding oral alimentation at time of data collection. Thirty-nine of 50 (78 %) adults requiring HFO2-NC were deemed medically appropriate by the intensivist and nursing to resume oral alimentation (n = 34) or with a functional swallow without aspiration on FEES (n = 5). All 39 (100 %) resumed oral alimentation successfully. Eleven of 50 (22 %) continued nil per os due to severe respiratory issues precluding both swallow testing and oral alimentation at time of data collection. All developmentally and medically appropriate neonatal and adult patients requiring HFO2-NC were successful with either the introduction or resumption of oral alimentation. Patients requiring HFO2-NC who are identified as having feeding or swallowing issues should be referred for swallowing evaluations using the same criteria as patients who do not require HFO2-NC, as it is not the use of HFO2-NC but rather patient-specific determinants of feeding and swallowing readiness and their underlying medical conditions that impact readiness for oral alimentation status.
- 1 May 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (5) , 1193-1199
Neonatal Sepsis 2004-2013: The Rise and Fall of Coagulase-Negative Staphylococci
- 1 May 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (5) , 1193-1199
Neonatal Sepsis 2004-2013: The Rise and Fall of Coagulase-Negative Staphylococci
- 3 July 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2014 (7) , CD005055
Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease
Nitric oxide (NO) is a prevalent molecule in humans that is responsible for many physiologic activities including pulmonary vasodilation. An exogenous, inhaled form (iNO) exists that mimics this action without affecting systemic blood pressure. This therapy has been implemented in the treatment of pulmonary hypertension. This review examines the efficacy of iNO in the postoperative management of infants and children with congenital heart disease (CHD). The original review was published in 2005, updated in 2008 and again in 2014. To compare the effects of postoperative administration of iNO versus placebo or conventional management, or both, on infants and children with CHD and pulmonary hypertension. The primary outcome was mortality. Secondary outcomes included length of hospital stay; neurodevelopmental disability; number of pulmonary hypertensive crises (PHTC); changes in mean pulmonary arterial pressure (MPAP), mean arterial pressure (MAP), and heart rate (HR); changes in oxygenation measured as the ratio of arterial oxygen tension (PaO2) to fraction of inspired oxygen (FiO2); and measurement of maximum methaemoglobin level as a marker of toxicity. In this updated version we extended the CENTRAL search to 2013, Issue 12 of The Cochrane Library, and MEDLINE and EMBASE through to 1 December 2013. The original search was performed in July 2004 and again in November 2007. We included abstracts and all languages. We included randomized and quasi-randomized controlled trials comparing iNO with placebo or conventional management, or both. Trials included only children with CHD requiring surgery complicated by pulmonary hypertension. Two authors extracted data. Data were collected on mortality; number of PHTC; changes in MPAP, MAP, HR, and PaO2:FiO2; and maximum methaemoglobin level. Data on long-term mortality, neurodevelopmental disability, and length of hospital stay were unavailable. We performed subgroup analysis by method of control (placebo or conventional management). We reran the searches to December 2013 and identified three new studies. These three studies did not fulfil our inclusion criteria. Therefore, no new studies were included in this updated review. In total four randomized trials involving 210 participants were included in this review. We observed no differences in mortality (OR 1.67, 95% CI 0.38 to 7.30; P = 0.50); PHTC (OR 0.80, 95% CI 0.15 to 4.18; P = 0.79); changes in MPAP (treatment effect -2.94 mm Hg, 95% CI -9.28 to 3.40; P = 0.36), MAP (treatment effect -3.55 mm Hg, 95% CI -11.86 to 4.76; P = 0.40), HR (treatment effect 0.02 bpm, 95% CI -8.13 to 8.18; P = 1.00), or PaO2:FiO2 (mean difference 17.18, 95% CI -28.21 to 62.57; P = 0.46). There was a significant increase in the methaemoglobin level (mean difference 0.30%, 95% CI 0.24 to 0.36; P < 0.00001) in patients treated with iNO, although levels did not reach toxicity levels. Data from long-term mortality, neurodevelopmental disability, and length of stay were not available. Two trials had a low risk of bias. Very low quality of the evidence was observed considering grading of the outcomes. We observed no differences with the use of iNO in the outcomes reviewed. No data were available for several clinical outcomes including long-term mortality and neurodevelopmental outcome. We found it difficult to draw valid conclusions given concerns regarding methodologic quality, sample size, and heterogeneity.
- 3 July 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2014 (7) , CD005055
Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease
Nitric oxide (NO) is a prevalent molecule in humans that is responsible for many physiologic activities including pulmonary vasodilation. An exogenous, inhaled form (iNO) exists that mimics this action without affecting systemic blood pressure. This therapy has been implemented in the treatment of pulmonary hypertension. This review examines the efficacy of iNO in the postoperative management of infants and children with congenital heart disease (CHD). The original review was published in 2005, updated in 2008 and again in 2014. To compare the effects of postoperative administration of iNO versus placebo or conventional management, or both, on infants and children with CHD and pulmonary hypertension. The primary outcome was mortality. Secondary outcomes included length of hospital stay; neurodevelopmental disability; number of pulmonary hypertensive crises (PHTC); changes in mean pulmonary arterial pressure (MPAP), mean arterial pressure (MAP), and heart rate (HR); changes in oxygenation measured as the ratio of arterial oxygen tension (PaO2) to fraction of inspired oxygen (FiO2); and measurement of maximum methaemoglobin level as a marker of toxicity. In this updated version we extended the CENTRAL search to 2013, Issue 12 of The Cochrane Library, and MEDLINE and EMBASE through to 1 December 2013. The original search was performed in July 2004 and again in November 2007. We included abstracts and all languages. We included randomized and quasi-randomized controlled trials comparing iNO with placebo or conventional management, or both. Trials included only children with CHD requiring surgery complicated by pulmonary hypertension. Two authors extracted data. Data were collected on mortality; number of PHTC; changes in MPAP, MAP, HR, and PaO2:FiO2; and maximum methaemoglobin level. Data on long-term mortality, neurodevelopmental disability, and length of hospital stay were unavailable. We performed subgroup analysis by method of control (placebo or conventional management). We reran the searches to December 2013 and identified three new studies. These three studies did not fulfil our inclusion criteria. Therefore, no new studies were included in this updated review. In total four randomized trials involving 210 participants were included in this review. We observed no differences in mortality (OR 1.67, 95% CI 0.38 to 7.30; P = 0.50); PHTC (OR 0.80, 95% CI 0.15 to 4.18; P = 0.79); changes in MPAP (treatment effect -2.94 mm Hg, 95% CI -9.28 to 3.40; P = 0.36), MAP (treatment effect -3.55 mm Hg, 95% CI -11.86 to 4.76; P = 0.40), HR (treatment effect 0.02 bpm, 95% CI -8.13 to 8.18; P = 1.00), or PaO2:FiO2 (mean difference 17.18, 95% CI -28.21 to 62.57; P = 0.46). There was a significant increase in the methaemoglobin level (mean difference 0.30%, 95% CI 0.24 to 0.36; P < 0.00001) in patients treated with iNO, although levels did not reach toxicity levels. Data from long-term mortality, neurodevelopmental disability, and length of stay were not available. Two trials had a low risk of bias. Very low quality of the evidence was observed considering grading of the outcomes. We observed no differences with the use of iNO in the outcomes reviewed. No data were available for several clinical outcomes including long-term mortality and neurodevelopmental outcome. We found it difficult to draw valid conclusions given concerns regarding methodologic quality, sample size, and heterogeneity.
- 1 January 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (1) , 61-66
Concurrent Bloodstream Infections in Infants with Necrotizing Enterocolitis
- 1 January 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (1) , 61-66
Concurrent Bloodstream Infections in Infants with Necrotizing Enterocolitis
- 26 September 2013
- Published by Springer Nature in Journal of Perinatology
- Vol. 34 (1) , 33-38
Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit
Objective: Study design: Result: Conclusion:
- 26 September 2013
- Published by Springer Nature in Journal of Perinatology
- Vol. 34 (1) , 33-38
Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit
Objective: Study design: Result: Conclusion:
- 1 December 2012
- Published by Elsevier in Seminars in Perinatology
- Vol. 36 (6) , 437-444
Health Care–Associated Infections in the Neonatal Intensive Care Unit: Barriers to Continued Success
- 1 December 2012
- Published by Elsevier in Seminars in Perinatology
- Vol. 36 (6) , 437-444
Health Care–Associated Infections in the Neonatal Intensive Care Unit: Barriers to Continued Success